Tesamorelin: FDA-Approved Peptide for Visceral Fat

Tesamorelin (brand name Egrifta) occupies a unique position in the peptide landscape: it is the only growth hormone releasing hormone (GHRH) analog with FDA approval, making it the most rigorously studied and clinically validated GHRH peptide available. Approved in 2010 for HIV-associated lipodystrophy — a condition where antiretroviral therapy causes abnormal visceral fat accumulation — tesamorelin has accumulated a substantial evidence base demonstrating its ability to reduce visceral adipose tissue through GH axis stimulation.

What Is Tesamorelin

Tesamorelin is a synthetic analog of human GHRH with the trans-3-hexenoic acid group added to stabilize the N-terminus against DPP-IV degradation. This modification extends the plasma half-life from the native GHRH's 7 minutes to approximately 26–38 minutes — long enough for effective subcutaneous absorption but short enough to preserve pulsatile GH release characteristics.

The drug is manufactured by Theratechnologies (Canada) and sold in the US under the name Egrifta SV (a newer formulation with simplified reconstitution). It requires a prescription from a licensed physician.

FDA Approval Data

The FDA approval was based on two Phase 3 randomized controlled trials:

LIPO trial: 412 HIV-positive adults with lipodystrophy received tesamorelin 2 mg/day or placebo subcutaneously for 26 weeks. The tesamorelin group showed:

• 15.2% reduction in visceral adipose tissue (VAT) by CT scan versus 1.5% in placebo group
• Significantly improved waist circumference
• Improved triglycerides (secondary endpoint)
• IGF-1 elevation within normal range
• No significant difference in blood glucose between groups

LPFARM trial: Confirmed the VAT reduction findings. 26-week extension data showed continued fat reduction with maintained long-term use. Discontinuation of tesamorelin results in return of VAT toward baseline within 6–12 months.

Mechanism of Action

Tesamorelin binds the GHRH receptor (GHRH-R) on pituitary somatotrophs, stimulating endogenous GH release. The GH pulse triggered by tesamorelin then:

1. Binds GH receptors on adipocytes, activating hormone-sensitive lipase (HSL)
2. Mobilizes triglycerides from visceral fat depots as free fatty acids
3. Promotes hepatic fat oxidation of the released fatty acids
4. Stimulates hepatic IGF-1 production (which provides anabolic and metabolic effects)

The visceral fat selectivity is a property of GH itself — GH receptors are more densely expressed in visceral adipose tissue than subcutaneous fat, so GH-driven lipolysis disproportionately reduces belly fat.

Off-Label Use in Non-HIV Adults

While FDA approval is for HIV lipodystrophy, physicians legally prescribe tesamorelin off-label for:

Age-related GH decline with visceral obesity: Older adults with documented low IGF-1 and excess visceral fat can benefit from tesamorelin's combined GH-elevating and fat-mobilizing effects.

Metabolic syndrome: The combination of elevated triglycerides, abdominal obesity, and insulin resistance seen in metabolic syndrome is theoretically addressable by tesamorelin's effects on visceral fat and lipid metabolism.

Non-alcoholic fatty liver disease (NAFLD): A 12-month randomized controlled trial (not in HIV patients) found tesamorelin 2 mg/day significantly reduced liver fat measured by MRI-PDFF (proton density fat fraction), with no worsening of insulin resistance — a finding with significant therapeutic implications.

Dosage and Administration

FDA-approved dose: 2 mg subcutaneously once daily Timing: Can be administered at any time of day; some physicians prefer morning dosing for consistent circadian alignment; others prefer evening for alignment with the natural GH sleep pulse Injection site: Abdomen (periumbilical region is the recommended site) Reconstitution: Egrifta SV comes as a lyophilized powder; follow manufacturer reconstitution instructions

Off-label dosing range: Some functional medicine physicians use 1–2 mg/day based on patient IGF-1 response. The goal is to bring IGF-1 to the upper quartile of the age-normal reference range without exceeding it.

Side Effects

Based on Phase 3 clinical trial data:

Common (>5%):

• Injection site reactions (redness, pain, induration): 25–30% of patients
• Arthralgia (joint pain): 13–16%
• Peripheral edema: 6–8%
• Myalgia: 5–7%

Metabolic:

• Glucose: No significant difference from placebo in the Phase 3 trials — a key distinguishing feature from other GH-elevating interventions that can impair insulin sensitivity
• IGF-1: Rises significantly but typically remains within the normal physiological range at 2 mg/day

Contraindications:

• Active malignancy (current or recent)
• Pituitary tumors or structural hypothalamic disease
• Pregnancy
• Hypopituitarism (does not help if the pituitary cannot respond)

Tesamorelin vs. Other Fat Loss Peptides

Tesamorelin's FDA approval and established safety profile give it credibility advantages over AOD-9604 and research-only GH secretagogues. However:

• It elevates IGF-1 (unlike AOD-9604), which is both an advantage (anabolic effects) and a concern (long-term IGF-1 elevation monitoring)
• It requires a physician prescription (unlike research-only compounds)
• It is significantly more expensive than research-grade peptides (brand Egrifta can cost several thousand dollars per month without insurance)

FAQ

How does tesamorelin compare to sermorelin for fat loss? Both are GHRH analogs that elevate GH and drive lipolysis. Tesamorelin has the advantage of FDA approval, extensive clinical trial data, and a validated 2 mg/day dose. Sermorelin is compoundable (cheaper) but requires more frequent dosing and has less Phase 3 fat-loss-specific data. For documented visceral fat reduction, tesamorelin has the stronger evidence base.

Will the fat come back after stopping tesamorelin? Yes — the Phase 3 trials showed that VAT returns toward baseline within 6–12 months of stopping tesamorelin. This means ongoing treatment is required to maintain the benefit, similar to other GH-based therapies.

Can I get tesamorelin without being HIV-positive? Physicians can prescribe it off-label for any indication they deem medically appropriate. Many anti-aging, functional medicine, and endocrinology practices prescribe tesamorelin for non-HIV adults with documented GH decline and visceral obesity. Cost and insurance coverage will vary significantly.

Related Articles

• Peptide Stack for Fat Loss: CJC-1295, AOD-9604, and Tesamorelin
• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It

Track your supplements in Optimize.